Compile Data Set for Download or QSAR
Report error Found 15 Enz. Inhib. hit(s) with all data for entry = 50007689
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511703(CHEMBL4454935)
Affinity DataIC50: 14nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511695(CHEMBL4573535)
Affinity DataIC50: 41nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511702(CHEMBL4562822)
Affinity DataIC50: 50nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511697(CHEMBL4475854)
Affinity DataIC50: 51nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511701(CHEMBL4555255)
Affinity DataIC50: 59nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511704(CHEMBL4470822)
Affinity DataIC50: 79nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511697(CHEMBL4475854)
Affinity DataIC50: 130nMAssay Description:Inhibition of RORgammat in human whole blood assessed as reduction in anti-CD3/anti-CD28 monoclonal antibodies/IL-18/IL-23-stimulated IL-17A producti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511700(CHEMBL4456847)
Affinity DataIC50: 130nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511707(CHEMBL4472584)
Affinity DataIC50: 230nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511705(CHEMBL4539359)
Affinity DataIC50: 240nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511706(CHEMBL4558889)
Affinity DataIC50: 590nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511696(CHEMBL4544850)
Affinity DataIC50: 1.50E+3nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511699(CHEMBL4442483)
Affinity DataIC50: 3.20E+3nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511698(CHEMBL4472208)
Affinity DataIC50: 8.00E+3nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetNuclear receptor ROR-gamma(Human)
Teijin Pharma

Curated by ChEMBL
LigandPNGBDBM50511708(CHEMBL4521811)
Affinity DataIC50: 1.00E+4nMAssay Description:Inverse agonist activity at recombinant human GAL4-fused RORgammat LBD (247 to 497 residues) transfected in HEK293T cells assessed as inhibition of R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed